These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 15848504

  • 21. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 22. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, Sirolimus Renal Function Study Group.
    Transplantation; 2002 Dec 15; 74(11):1560-7. PubMed ID: 12490789
    [Abstract] [Full Text] [Related]

  • 23. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
    Friend P, Russ G, Oberbauer R, Murgia MG, Tufveson G, Chapman J, Blancho G, Mota A, Grandaliano G, Campistol JM, Brault Y, Burke JT, Rapamune Maintenance Regimen (RMR) Study Group.
    Transpl Int; 2007 Sep 15; 20(9):754-60. PubMed ID: 17565578
    [Abstract] [Full Text] [Related]

  • 24. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar 15; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 25. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T, Kreis H, Friend P.
    Clin Transplant; 2004 Aug 15; 18(4):446-9. PubMed ID: 15233824
    [Abstract] [Full Text] [Related]

  • 26. Economic evaluation of sirolimus-based immunosuppressive regimens in kidney graft recipients.
    Niemczyk M, Nowak M, Pilecki T, Wyzgał J, Ziółkowski J, Zygier D, Paczek L.
    Transplant Proc; 2006 Aug 15; 38(1):74-7. PubMed ID: 16504668
    [Abstract] [Full Text] [Related]

  • 27. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor.
    Durrbach A, Rostaing L, Tricot L, Ouali N, Wolf P, Pouteil-Noble C, Kessler M, Viron B, Thervet E.
    Transplantation; 2008 Feb 15; 85(3):486-90. PubMed ID: 18301342
    [Abstract] [Full Text] [Related]

  • 28. The effect of sirolimus in the development of chronic allograft nephropathy.
    Gürkan A, Kaçar S, Erdoğdu U, Varilsüha C, Kandemir G, Karaca C, Akman F.
    Transplant Proc; 2008 Feb 15; 40(1):114-6. PubMed ID: 18261561
    [Abstract] [Full Text] [Related]

  • 29. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ.
    Clin Transplant; 2005 Feb 15; 19(1):130-6. PubMed ID: 15659146
    [Abstract] [Full Text] [Related]

  • 30. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [Abstract] [Full Text] [Related]

  • 31. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
    van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L.
    Transplantation; 2003 Jun 27; 75(12):1934-9. PubMed ID: 12829890
    [Abstract] [Full Text] [Related]

  • 32. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial.
    Oberbauer R, Hutchison B, Eris J, Arias M, Claesson K, Mota A, Kreis H, Kleinman L, Wang F, Chen J, Revicki DA, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Apr 27; 75(8):1277-85. PubMed ID: 12717216
    [Abstract] [Full Text] [Related]

  • 33. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 34. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

  • 35. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
    Steigerwalt SP, Brar N, Dhungel A, Butcher D, Steigerwalt S, El-Ghouroury M, Provenzano R.
    Transplant Proc; 2009 Dec 27; 41(10):4184-7. PubMed ID: 20005365
    [Abstract] [Full Text] [Related]

  • 36. Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant.
    Mourad G, Karras A, Kamar N, Garrigue V, Legendre C, Lefrançois N, Charpentier B, Bourbigot B, Pouteil-Noble C, Bayle F, Lebranchu Y, Mariat C, Le Meur Y, Kessler M, Moulin B, Ducloux D, Delahousse M, Lang P, Merville P, Chaouche-Teyara K, Rostaing L, French Myriade FR01 Study Group.
    Clin Transplant; 2007 Dec 27; 21(3):295-300. PubMed ID: 17488375
    [Abstract] [Full Text] [Related]

  • 37. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 38. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M.
    Saudi J Kidney Dis Transpl; 2008 Jul 27; 19(4):564-70. PubMed ID: 18580014
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
    Transplant Proc; 2005 Mar 27; 37(2):864-6. PubMed ID: 15848558
    [Abstract] [Full Text] [Related]

  • 40. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
    Flechner SM, Gurkan A, Hartmann A, Legendre CM, Russ GR, Campistol JM, Schena FP, Hahn CM, Li H, Korth-Bradley JM, Tai SS, Schulman SL.
    Transplantation; 2013 May 27; 95(10):1233-41. PubMed ID: 23689085
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.